Hospira Reports ‘More Issues’ Than Previously Thought, Some Progress in Manufacturing Remediation

Amid lingering quality issues at a number of its manufacturing plants, Hospira reported some success in its discussions with the FDA but notes there are more trouble spots than the company previously thought. “We are trying to drive to the surface all the issues we can in 2012 and take care of them,” Thomas Werner, chief financial officer, said during the company’s second-quarter conference call.
Drug Industry Daily